MARKET

EDSA

EDSA

Edesa Biotech Inc
NASDAQ
5.59
+0.48
+9.39%
Opening 10:27 07/26 EDT
OPEN
5.24
PREV CLOSE
5.11
HIGH
5.59
LOW
5.24
VOLUME
5.09K
TURNOVER
0
52 WEEK HIGH
8.33
52 WEEK LOW
2.460
MARKET CAP
17.98M
P/E (TTM)
-2.3600
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EDSA last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at EDSA last week (0708-0712)?
Weekly Report · 07/15 10:45
Weekly Report: what happened at EDSA last week (0701-0705)?
Weekly Report · 07/08 10:47
Weekly Report: what happened at EDSA last week (0624-0628)?
Weekly Report · 07/01 10:47
Edesa Biotech Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 06/28 11:44
HC Wainwright & Co. Reiterates Buy on Edesa Biotech, Maintains $21 Price Target
Benzinga · 06/28 11:33
Promising Outlook for Edesa Biotech’s Paridiprubart: A Buy Rating Justified by BARDA-Backed ARDS Study and Broad Therapeutic Potential
TipRanks · 06/28 10:17
Edesa Biotech’s ARDS Drug Chosen for US Trial
TipRanks · 06/24 12:51
More
About EDSA
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.

Webull offers Edesa Biotech Inc stock information, including NASDAQ: EDSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDSA stock methods without spending real money on the virtual paper trading platform.